Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

bluebird bio, Inc.

Complete the rolling BLA submission to the U.S. FDA for beti-cel

Delivered after the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
23 Feb 2021
Due
30 Jun 2021
Delivered
September 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“The company is on track to complete its rolling BLA submission to the U.S. FDA for beti-cel in mid-2021, contingent upon successful resolution of any U.S. FDA concerns”

What we found

Evidence strength A What the grades mean

bluebird bio said in July 2021 it was still on track for mid-2021 BLA completion; a November 2021 filing says the submission was completed in September 2021, after the June 30 deadline.

  • A
    bluebird bio, Inc. 8-K filed 2021-07-09 Regulatory filing · published 9 Jul 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “bluebird bio is on track to complete its rolling Biologics License Application (BLA) submission to the FDA for beti-cel in mid-2021.” ✓ confirmed on the page
  • A
    bluebird bio, Inc. 10-Q filed 2021-11-05 Regulatory filing · published 5 Nov 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “In September 2021, we completed the submission of our BLA to the FDA for beti-cel in adult, adolescent, and pediatric patients with β-thalassemia” ✓ confirmed on the page

Checked 26 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Regulatory other
Indicative materiality
Medium rules
Action
Complete
Deliverable
Rolling BLA submission to U.S. FDA for beti-cel
Where
United States
Language
Firm (“will”, “on track to”)
In the company’s control
Medium
Specificity
High
Conditional
Yes: contingent upon successful resolution of any U.S. FDA concerns from SCD safety events
Depends on
Regulatory

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you bluebird bio, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-C293971-024249 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.